Management of retinal vascular diseases: a patient-centric approach

Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments. Vascular endothelial growth factor (VEGF) has been implicated in certain retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO). Treatment of wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO with an anti-VEGF on an as needed basis, rather than a fixed schedule, allows an individualised treatment approach; providing treatment when patients are most likely to benefit from it, while minimising the number of unnecessary intravitreal injections. Thus, an individualised treatment regimen reduces the chances of over-treatment and under-treatment, optimising both the risk/benefit profile of the treatment and the efficient use of NHS resource. Streamlining of treatment for patients with wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO, by using one treatment with similar posology across all three diseases, may help to minimise burden of clinic capacity and complexity and hence optimise patient outcomes. Informed treatment decisions and efficient clinic throughput are important for optimal patient outcomes in the fast-changing field of retinal vascular diseases.

[1]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[2]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[3]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.

[4]  H. Yamashita,et al.  Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  Judy E. Kim,et al.  Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. , 2009, Archives of ophthalmology.

[6]  D. Finkelstein,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1986, Ophthalmology.

[7]  A. Tufail,et al.  Age-related macular degeneration: diagnosis and management. , 2008, British medical bulletin.

[8]  F L Ferris,et al.  Photocoagulation for diabetic macular edema. , 1987, Archives of ophthalmology.

[9]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[10]  I. Scott,et al.  Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update , 2011, Advances in therapy.

[11]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[12]  C. Bunce,et al.  Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008 , 2010, Eye.

[13]  P. Mitchell,et al.  The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. , 2010, Investigative ophthalmology & visual science.

[14]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[15]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[16]  J. F. Cullen.  Retinal Vascular Disease , 1968, Scottish medical journal.

[17]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[18]  I. Scott,et al.  Management of macular edema secondary to central retinal vein occlusion: an evidence-based , 2011, Advances in therapy.

[19]  Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[20]  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. , 1985, Archives of ophthalmology.

[21]  M. Crawford.  The Human Genome Project. , 1990, Human biology.

[22]  P. Charbel Issa,et al.  The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[23]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[24]  J. Pulido,et al.  Role of inflammation in retinal vein occlusion. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[25]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[26]  S D Miller,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1985, American journal of ophthalmology.

[27]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[28]  F. Boscia.  Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema , 2010, Drugs.

[29]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[30]  R. Klein,et al.  The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. , 2000, Transactions of the American Ophthalmological Society.

[31]  Lloyd Paul Aiello.  A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. , 2008, Ophthalmology.

[32]  E. Wilkinson.  Cancer Research UK , 2002 .

[33]  C. Bunce,et al.  Causes of blind certifications in England and Wales: April 1999–March 2000 , 2008, Eye.

[34]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[35]  H. Wieland,et al.  Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. , 1997, American journal of respiratory cell and molecular biology.

[36]  Simon P Harding,et al.  Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study , 2003, The Lancet.

[37]  Kang Zhang,et al.  Age-related macular degeneration: genetic and environmental factors of disease. , 2010, Molecular interventions.

[38]  I. MacDonald,et al.  In Memoriam: Dr. Lois Lloyd and Dr. Ronald Casey , 2007 .

[39]  F. Bandello,et al.  Retinal Vein Occlusion: Current Treatment , 2010, Ophthalmologica.

[40]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[41]  J. Slakter,et al.  Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. , 2009, American journal of ophthalmology.

[42]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. , 1987, Ophthalmology.

[43]  G. Karakiulakis,et al.  Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. , 1998, European journal of pharmacology.

[44]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[45]  A. Chakravarti.  Single nucleotide polymorphisms: . . .to a future of genetic medicine , 2001, Nature.

[46]  R. Avery,et al.  Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. , 2007, Ophthalmology.

[47]  T. Ianchulev,et al.  A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[48]  Jennifer I. Lim,et al.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. , 2009, Ophthalmology.

[49]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[50]  I. Cree,et al.  Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. , 2002, Archives of ophthalmology.

[51]  J. Folkman,et al.  Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .

[52]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[53]  T. Liesegang.  The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Klein R, ∗ Klein BEK, Moss SE, Meuer SM. Tr Am Ophth Soc 2000;98:133–143. , 2001 .

[54]  Eric N Brown,et al.  Complement, age-related macular degeneration and a vision of the future. , 2010, Archives of ophthalmology.

[55]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.

[56]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[57]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[58]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[59]  Allen C Ho,et al.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. , 2011, Ophthalmology.

[60]  R. Guymer,et al.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.

[61]  M V Olson,et al.  The human genome project. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Sharon D. Solomon,et al.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  London,et al.  Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. , 1982, The British journal of ophthalmology.